BETA: Please send your feedback!
Flexion Therapeutics
FLXN:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2021
—
About
Biotechnology
Founded 2007
Flexion Therapeutics, Inc. is a pharmaceutical company, which focuses on the development and commercialization of novel, local therapies. The firm specializes in treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.
website
Headquarters
Executives
| Name | Title | Gender |
| Kerry A. Wentworth | Vice President-Regulatory Affairs & Quality | Female |
| Scott D. Kelley, MD | Vice President-Medical Affairs | Male |
| Patrick J. Mahaffy | Chairman | Male |
| Michael D. Clayman, MD | President, Chief Executive Officer, CFO & Director | Male |
| Neil Bodick, MD, PhD | Chief Scientific Officer | Male |
| Yamo Deniz, MD | Chief Medical Officer | Male |
| Rose Villandry | Vice President-Human Resources | Female |
| Dan Leblanc | Senior Vice President-CMC Operations | Male |
| Scott Young | Senior Director-Corporate Communications & IR | Male |
Mindful Investing Summary
Flexion Therapeutics - Competitors and Related Companies
How Flexion Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.
Flexion Therapeutics
FLXN:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2021
—
CARA Therapeutics
CARA:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2021
—
Pacira Pharmaceuticals
PCRX:NAS
Pharmaceuticals: Other
—
SMALL cap
(—)
—
since start of 2021
—
AcelRx Pharmaceuticals
ACRX:NAS
Pharmaceuticals: Other
—
MICRO cap
(—)
—
since start of 2021
—
Recro Pharma
REPH:NAS
Biotechnology
—
MICRO cap
(—)
—
since start of 2021
—
Johnson & Johnson
JNJ:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2021
—